Vera Therapeutics/VERA

$47.97

-3.51%
-
1D1W1MYTD1YMAX

About Vera Therapeutics

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.

Ticker

VERA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Marshall Fordyce

Employees

51

Headquarters

Brisbane, United States
Website
veratx.com

VERA Metrics

BasicAdvanced
$2.61B
Market cap
-
P/E ratio
-$2.28
EPS
-
Beta
-
Dividend rate
$2.61B
$50.78
$6.05
1.37M
7.713
49.051
49.051
-62.54%
-107.5%
-74.1%
20.97
25.688
31.83%

What the Analysts think about VERA

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 8 analysts.
1.9% upside
High $60.00
Low $25.00
$47.97
Current price
$48.88
Average price target

VERA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-25.6M
27.36%
Profit margin
0%
-

VERA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 18.16%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.80
-$0.46
-$0.45
-$0.60
-
Expected
-$0.60
-$0.69
-$0.53
-$0.51
-$0.53
Surprise
32.45%
-33.65%
-15.62%
18.16%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Vera Therapeutics stock?

Vera Therapeutics (VERA) has a market cap of $2.61B as of April 14, 2024.

What is the P/E ratio for Vera Therapeutics stock?

The price to earnings (P/E) ratio for Vera Therapeutics (VERA) stock is 0 as of April 14, 2024.

Does Vera Therapeutics stock pay dividends?

No, Vera Therapeutics (VERA) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Vera Therapeutics dividend payment date?

Vera Therapeutics (VERA) stock does not pay dividends to its shareholders.

What is the beta indicator for Vera Therapeutics?

Vera Therapeutics (VERA) does not currently have a Beta indicator.

What is the Vera Therapeutics stock price target?

The target price for Vera Therapeutics (VERA) stock is $48.88, which is 1.9% above the current price of $47.97. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Vera Therapeutics stock

Buy or sell Vera Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing